HIM
ALXN

Hermes Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Hermes Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-1,700
Closed -$315K – 234
2014
Q4 		$315K Hold
1,700
– – 0.01% 218
2014
Q3 		$282K Hold
1,700
– – 0.01% 220
2014
Q2 		$266K Hold
1,700
– – 0.01% 237
2014
Q1 		$259K Hold
1,700
– – 0.01% 239
2013
Q4 		$226K Buy
+1,700
New +$204K 0.01% 241

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Hermes Investment Management's ALXN Position: Q1 2015 in Review

Hermes Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 1,700 shares — an estimated $315K sold.

Hermes Investment Management first reported a position in ALXN in Q4 2013 and held it in 5 quarters. The position peaked at $315K in Q4 2014. 565 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

  • Hermes Investment Management reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Hermes Investment Management sold 1,700 Alexion Pharmaceuticals shares in Q1 2015, an estimated $315K.
  • Hermes Investment Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 5 quarters.
  • Hermes Investment Management's Alexion Pharmaceuticals position peaked at $315K in Q4 2014.
  • 565 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Hermes Investment Management's 13F filing for Q1 2015, filed 7 May 2015.